Analyst Price Targets — BTAI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| September 23, 2024 7:04 am | Graig Suvannavejh | Mizuho Securities | $1.00 | $0.59 | StreetInsider | Mizuho Reiterates Neutral Rating on BioXcel Therapeutics (BTAI) |
| April 15, 2024 6:44 am | Raghuram Selvaraju | H.C. Wainwright | $10.00 | $2.90 | StreetInsider | BioXcel Therapeutics (BTAI) PT Lowered to $10 at H.C. Wainwright |
| August 15, 2023 2:02 pm | Graig Suvannavejh | Mizuho Securities | $4.00 | $3.98 | Benzinga | Challenging Horizon For BioXcel: Analysts Dive Into Igalmi's Potential And Reshaped Commercialization Strategy |
| January 3, 2023 6:12 am | — | H.C. Wainwright | $73.00 | $21.48 | Benzinga | HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $73 |
| November 11, 2022 8:50 am | — | Guggenheim | $25.00 | $14.82 | Benzinga | Guggenheim Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $25 |
Latest News for BTAI
BioXcel Therapeutics (NASDAQ: BTAI) outlined its commercial strategy and launch preparations for IGALMI as it awaits a U.S. Food and Drug Administration decision on an expanded label for at-home treatment of acute agitation episodes associated with bipolar disorder and schizophrenia. The company is working toward a November 14 PDUFA target action date for its supplemental new
BioXcel Therapeutics, Inc. (BTAI) Discusses Commercial Launch Strategy and Market Opportunity for IGALMI in At-Home Setting Transcript
Live event to be held on Thursday, April 23, at 2:00 p.m. ET Company focused on advancing launch strategy ahead of November 14 PDUFA target action date NEW HAVEN, Conn.
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
DoW-funded Phase 2a trial led by University of North Carolina at Chapel Hill (UNC) Institute for Trauma Recovery Positive outcomes from trial can potentially impact Veteran Affairs/Department of War Clinical Practice Guidelines for management of acute stress reactions (ASR) NEW HAVEN, Conn., April 08, 2026 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company built on artificial…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BTAI.
U.S. House Trading
No House trades found for BTAI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.